FASTAU: RNA binding motifs as therapeutic targets for Angelman Syndrome | $265,619.00

This proposal will investigate the mechanism by which the UBE3A-ATS achieves silencing of UBE3A, which is currently unknown. We hypothesize that UBE3A-ATS silences UBE3A by an epigenetic mechanism that involves the 3′ end of UBE3A-ATS.

X
X